High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share
As Roche’s Vabysmo Mounts Threat
Executive Summary
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.
You may also be interested in...
Regeneron Hopes Its High-Dose Aflibercept Will Ease Eylea Pressure
Eylea sales were below consensus for the second quarter in a row, but aflibercept 8mg approval in late June could offset the decline. Also, a late 2023 filing is planned for linvoseltamab in myeloma.
Stock Watch: Regeneron’s Constellation of Ophthalmic Competition
The accepted commercial dynamics of a competitive indication in older patients can be disrupted by new entrants with improved profiles, lower priced biosimilar competition and (soon) Medicare price negotiations.
Roche’s Vabysmo Advantage Over Eylea Hard To See In Latest Head-To-Head
Roche’s next-generation eye drug Vabysmo has enjoyed a strong launch, but new head-to-head trials in a potential new indication, retinal vein occlusion, appear to offers up few advantages over market leader Eylea.